| Name | Title | Contact Details |
|---|---|---|
Gene Kalil |
Director of Information Technology | Profile |
Hallow: A Catholic prayer & meditation app to help you find peace, deepen your relationship with God, and sleep soundly every night.
Iris Plans provides telehealth Advance Care Planning (ACP) services to health insurers and health care providers, reducing unnecessary care for people with serious medical conditions. ACP lowers the cost of care while improving quality and experience.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
GoHealth Urgent Care is one of the countrys fastest-growing and largest urgent care providers. At GoHealth Urgent Care, we place the needs of our patients first—by providing an effortless patient experience, a welcoming culture of care and seamless integration with market-leading health systems and our communities. GoHealth Urgent Care operates 80 urgent care centers in the New York and Portland, Oregon, metropolitan areas, the San Francisco Bay Area, Hartford, Connecticut, and will soon open urgent care centers in multiple Midwest markets. GoHealth Urgent Cares current partners include health systems that are at the forefront of care delivery innovation, including Northwell Health, New Yorks largest health system, Legacy Health, the largest nonprofit, locally owned health system in the Portland-Vancouver area, Dignity Health, one of the nations largest health care systems, headquartered in San Francisco, Hartford HealthCare, Connecticuts most comprehensive health care network, and now Mercy, one of the Midwests largest, most integrated and innovative health systems.
Frantz Medical Group is a Mentor, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.